Publication Name	World Journal of Clinical Cases
Manuscript ID	87158
Country	China

Received	2023-08-23 09:19
Peer-Review Started	2023-08-23 09:19
To Make the First Decision
Return for Revision	2023-09-13 02:06
Revised	2023-10-09 13:19
Second Decision	2023-10-19 02:24
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2023-10-23 03:32
Articles in Press	2023-10-23 03:32
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2023-10-31 03:51
Publish the Manuscript Online	2023-11-06 09:10

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Observational Study
Article Title	Network pharmacological and molecular docking study of the effect of Liu-Wei-Bu-Qi capsule on lung cancer
Manuscript Source	Unsolicited Manuscript
All Author List	Qing Yang and Li-Yuan Li
ORCID	Author(s) ORCID Number Qing Yang http://orcid.org/0009-0007-8575-3069
Funding Agency and Grant Number
Corresponding Author	Qing Yang, MMed, Doctor, Doctor, The Second Department of Oncology, The First Affiliated Hospital of Anhui University of Chinese Medicine, No. 117 Meishan Road, Hefei 230031, Anhui Province, China. cbdcnmyy929@sina.com
Key Words	Liu-Wei-Bu-Qi capsule; Lung cancer; Network pharmacology; Molecular docking; Active ingredients; Signaling pathways
Core Tip	The network pharmacological and molecular docking study of Liu-Wei-Bu-Qi capsule (LBC) on lung cancer revealed that LBC's active ingredients target multiple signaling pathways, including the endothelial growth factor, toll-like receptor, prolactin, FoxO, PI3K-Akt, and HIF-1 pathways. Quercetin, found in LBC, showed promising affinity for MAPK3, highlighting its potential role in lung cancer treatment. These findings provide valuable insights into the mechanisms of action of LBC and pave the way for further investigations into its therapeutic effects on lung cancer.
Publish Date	2023-11-06 09:10
Citation	Yang Q, Li LY. Network pharmacological and molecular docking study of the effect of Liu-Wei-Bu-Qi capsule on lung cancer. World J Clin Cases 2023; 11(31): 7593-7609
URL	https://www.wjgnet.com/2307-8960/full/v11/i31/7593.htm
DOI	https://dx.doi.org/10.12998/wjcc.v11.i31.7593

Full Article (PDF)	WJCC-11-7593-with-cover.pdf
Full Article (Word)	WJCC-11-7593.docx
STROBE Statement	87158-STROBE statement.pdf
Manuscript File	87158_Auto_Edited-LJH-JLW.docx
Answering Reviewers	87158-Answering reviewers.pdf
Audio Core Tip	87158-Audio core tip.mp3
Biostatistics Review Certificate	87158-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	87158-Conflict-of-interest statement.pdf
Copyright License Agreement	87158-Copyright license agreement.pdf
Institutional Review Board Approval Form or Document	87158-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	87158-Language certificate.pdf
Peer-review Report	87158-Peer-review(s).pdf
Scientific Misconduct Check	87158-Bing-Liu JH-2.png
Scientific Misconduct Check	87158-CrossCheck.png
Scientific Editor Work List	87158-Scientific editor work list.pdf
CrossCheck Report	87158-CrossCheck report.pdf